• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed by Adaptimmune Therapeutics plc (Amendment)

    4/2/24 8:38:07 PM ET
    $ADAP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ADAP alert in real time by email
    SC 13D/A 1 nea14-adaptimmune_18818.htm NEW ENTERPRISE ASSOCIATES 14, L.P. -- ADAPTIMMUNE 13D/A(#2) Schedule 13D

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13D

     

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 2)*

     

     

    Adaptimmune Therapeutics Plc

    (Name of Issuer)

    Ordinary Shares, £.001 par value per share

    (Title of Class of Securities)

    00653A107

    (CUSIP Number)

    Stephanie Brecher

    New Enterprise Associates

    1954 Greenspring Drive, Suite 600, Timonium, MD 21093

    (410) 842-4000

    (Name, Address and Telephone Number of Person

    Authorized to Receive Notices and Communications)

    April 1, 2024

    (Date of Event which Requires Filing of this Statement)

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ☐

    Note:  Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties to whom copies are to be sent.

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

    CUSIP No. 00653A107

    13D Page 2 of 22 Pages    

     

    1.  

    NAMES OF REPORTING PERSONS.

     

    New Enterprise Associates 14, L.P.

     

       
    2.  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

     

     

     

     

    (a) ☐

    (b) ☐

    3.  

    SEC USE ONLY

     

     

     

       
    4.  

    SOURCE OF FUNDS (see instructions)

      

    WC

     

       
    5.  

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)     

     

     

     

       ☐
    6.  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Cayman Islands

      

       
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH  

     7.

     

    SOLE VOTING POWER

     

    0 Shares

     

      8.  

    SHARED VOTING POWER

     

    102,478,672 Shares

     

      9.  

    SOLE DISPOSITIVE POWER

     

    0 Shares

     

      10.  

    SHARED DISPOSITIVE POWER

     

    102,478,672 Shares

     

    11.  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    102,478,672 Shares

     

       
    12.  

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions)    

     

     

     

       ☐
    13.  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

      

    6.7%

     

       

     14.

     

    TYPE OF REPORTING PERSON (see instructions)

       

    PN

     

       

     

     

     

    CUSIP No. 00653A107

    13D Page 3 of 22 Pages    

     

    1.  

    NAMES OF REPORTING PERSONS.

     

    NEA Partners 14, L.P.

     

       
    2.  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

     

     

     

     

    (a) ☐

    (b) ☐

    3.  

    SEC USE ONLY

     

     

     

       
    4.  

    SOURCE OF FUNDS (see instructions)

      

    AF

     

       
    5.  

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)     

     

     

     

       ☐
    6.  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Cayman Islands

      

       
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH  

     7.

     

    SOLE VOTING POWER

     

    0 Shares

     

      8.  

    SHARED VOTING POWER

     

    102,478,672 Shares

     

      9.  

    SOLE DISPOSITIVE POWER

     

    0 Shares

     

      10.  

    SHARED DISPOSITIVE POWER

     

    102,478,672 Shares

     

    11.  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    102,478,672 Shares

     

       
    12.  

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions)    

     

     

     

       ☐
    13.  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

      

    6.7%

     

       

     14.

     

    TYPE OF REPORTING PERSON (see instructions)

       

    PN

     

       

     

     

     

     CUSIP No. 00653A107

    13D Page 4 of 22 Pages    

     

    1.  

    NAMES OF REPORTING PERSONS.

     

    NEA 14 GP, LTD

     

       
    2.  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

     

     

     

     

    (a) ☐

    (b) ☐

    3.  

    SEC USE ONLY

     

     

     

       
    4.  

    SOURCE OF FUNDS (see instructions)

      

    AF

     

       
    5.  

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)     

     

     

     

       ☐
    6.  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Cayman Islands

      

       
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH  

     7.

     

    SOLE VOTING POWER

     

    0 Shares

     

      8.  

    SHARED VOTING POWER

     

    102,478,672 Shares

     

      9.  

    SOLE DISPOSITIVE POWER

     

    0 Shares

     

      10.  

    SHARED DISPOSITIVE POWER

     

    102,478,672 Shares

     

    11.  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    102,478,672 Shares

     

       
    12.  

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions)    

     

     

     

       ☐
    13.  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

      

    6.7%

     

       

     14.

     

    TYPE OF REPORTING PERSON (see instructions)

       

    CO

     

       

     

     

    CUSIP No. 00653A107

    13D Page 5 of 22 Pages    

     

    1.  

    NAMES OF REPORTING PERSONS.

     

    New Enterprise Associates 16, L.P.

     

       
    2.  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

     

     

     

     

    (a) ☐

    (b) ☐

    3.  

    SEC USE ONLY

     

     

     

       
    4.  

    SOURCE OF FUNDS (see instructions)

      

    WC

     

       
    5.  

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)     

     

     

     

       ☐
    6.  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

      

       
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH  

     7.

     

    SOLE VOTING POWER

     

    0 Shares

     

      8.  

    SHARED VOTING POWER

     

    102,478,672 Shares

     

      9.  

    SOLE DISPOSITIVE POWER

     

    0 Shares

     

      10.  

    SHARED DISPOSITIVE POWER

     

    102,478,672 Shares

     

    11.  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    102,478,672 Shares

     

       
    12.  

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions)    

     

     

     

       ☐
    13.  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

      

    6.7%

     

       

     14.

     

    TYPE OF REPORTING PERSON (see instructions)

       

    PN

     

       

     

     

    CUSIP No. 00653A107

    13D Page 6 of 22 Pages    

     

    1.  

    NAMES OF REPORTING PERSONS.

     

    NEA Partners 16, L.P.

     

       
    2.  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

     

     

     

     

    (a) ☐

    (b) ☐

    3.  

    SEC USE ONLY

     

     

     

       
    4.  

    SOURCE OF FUNDS (see instructions)

      

    AF

     

       
    5.  

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)     

     

     

     

       ☐
    6.  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

      

       
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH  

     7.

     

    SOLE VOTING POWER

     

    0 Shares

     

      8.  

    SHARED VOTING POWER

     

    102,478,672 Shares

     

      9.  

    SOLE DISPOSITIVE POWER

     

    0 Shares

     

      10.  

    SHARED DISPOSITIVE POWER

     

    102,478,672 Shares

     

    11.  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    102,478,672 Shares

     

       
    12.  

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions)    

     

     

     

       ☐
    13.  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

      

    6.7%

     

       

     14.

     

    TYPE OF REPORTING PERSON (see instructions)

       

    PN

     

       

     

     

    CUSIP No. 00653A107

    13D Page 7 of 22 Pages    

     

    1.  

    NAMES OF REPORTING PERSONS.

     

    NEA 16 GP, LLC

     

       
    2.  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

     

     

     

     

    (a) ☐

    (b) ☐

    3.  

    SEC USE ONLY

     

     

     

       
    4.  

    SOURCE OF FUNDS (see instructions)

      

    AF

     

       
    5.  

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)     

     

     

     

       ☐
    6.  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

      

       
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH  

     7.

     

    SOLE VOTING POWER

     

    0 Shares

     

      8.  

    SHARED VOTING POWER

     

    102,478,672 Shares

     

      9.  

    SOLE DISPOSITIVE POWER

     

    0 Shares

     

      10.  

    SHARED DISPOSITIVE POWER

     

    102,478,672 Shares

     

    11.  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    102,478,672 Shares

     

       
    12.  

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions)    

     

     

     

       ☐
    13.  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

      

    6.7%

     

       

     14.

     

    TYPE OF REPORTING PERSON (see instructions)

       

    OO

     

       

     

     

      

      CUSIP No. 00653A107

    13D Page 8 of 22 Pages    

     

    1.  

    NAMES OF REPORTING PERSONS.

     

    Forest Baskett

     

       
    2.  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

     

     

     

     

    (a) ☐

    (b) ☐

    3.  

    SEC USE ONLY

     

     

     

       
    4.  

    SOURCE OF FUNDS (see instructions)

      

    AF

     

       
    5.  

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)     

     

     

     

       ☐
    6.  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States

      

       
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH  

     7.

     

    SOLE VOTING POWER

     

    0 Shares

     

      8.  

    SHARED VOTING POWER

     

    102,478,672 Shares

     

      9.  

    SOLE DISPOSITIVE POWER

     

    0 Shares

     

      10.  

    SHARED DISPOSITIVE POWER

     

    102,478,672 Shares

     

    11.  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    102,478,672 Shares

     

       
    12.  

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions)    

     

     

     

       ☐
    13.  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

      

    6.7%

     

       

     14.

     

    TYPE OF REPORTING PERSON (see instructions)

       

    IN

     

       

     

     

    CUSIP No. 00653A107

    13D Page 9 of 22 Pages    

     

    1.  

    NAMES OF REPORTING PERSONS.

     

    Anthony A. Florence, Jr.

     

       
    2.  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

     

     

     

     

    (a) ☐

    (b) ☐

    3.  

    SEC USE ONLY

     

     

     

       
    4.  

    SOURCE OF FUNDS (see instructions)

      

    AF

     

       
    5.  

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)     

     

     

     

       ☐
    6.  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States

      

       
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH  

     7.

     

    SOLE VOTING POWER

     

    0 Shares

     

      8.  

    SHARED VOTING POWER

     

    102,478,672 Shares

     

      9.  

    SOLE DISPOSITIVE POWER

     

    0 Shares

     

      10.  

    SHARED DISPOSITIVE POWER

     

    102,478,672 Shares

     

    11.  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    102,478,672 Shares

     

       
    12.  

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions)    

     

     

     

       ☐
    13.  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

      

    6.7%

     

       

     14.

     

    TYPE OF REPORTING PERSON (see instructions)

       

    IN

     

       

     

     

    CUSIP No. 00653A107

    13D Page 10 of 22 Pages    

     

    1.  

    NAMES OF REPORTING PERSONS.

     

    Patrick J. Kerins

     

       
    2.  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

     

     

     

     

    (a) ☐

    (b) ☐

    3.  

    SEC USE ONLY

     

     

     

       
    4.  

    SOURCE OF FUNDS (see instructions)

      

    AF

     

       
    5.  

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)     

     

     

     

       ☐
    6.  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States

      

       
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH  

     7.

     

    SOLE VOTING POWER

     

    0 Shares

     

      8.  

    SHARED VOTING POWER

     

    82,978,672 Shares

     

      9.  

    SOLE DISPOSITIVE POWER

     

    0 Shares

     

      10.  

    SHARED DISPOSITIVE POWER

     

    82,978,672 Shares

     

    11.  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    82,978,672 Shares

     

       
    12.  

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions)    

     

     

     

       ☐
    13.  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

      

    5.4%

     

       

     14.

     

    TYPE OF REPORTING PERSON (see instructions)

       

    IN

     

       

     

     

    CUSIP No. 00653A107

    13D Page 11 of 22 Pages    

     

    1.  

    NAMES OF REPORTING PERSONS.

     

    Mohamad H. Makhzoumi

     

       
    2.  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

     

     

     

     

    (a) ☐

    (b) ☐

    3.  

    SEC USE ONLY

     

     

     

       
    4.  

    SOURCE OF FUNDS (see instructions)

      

    AF

     

       
    5.  

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)     

     

     

     

       ☐
    6.  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States

      

       
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH  

     7.

     

    SOLE VOTING POWER

     

    0 Shares

     

      8.  

    SHARED VOTING POWER

     

    102,478,672 Shares

     

      9.  

    SOLE DISPOSITIVE POWER

     

    0 Shares

     

      10.  

    SHARED DISPOSITIVE POWER

     

    102,478,672 Shares

     

    11.  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    102,478,672 Shares

     

       
    12.  

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions)    

     

     

     

       ☐
    13.  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

      

    6.7%

     

       

     14.

     

    TYPE OF REPORTING PERSON (see instructions)

       

    IN

     

       

     

     

    CUSIP No. 00653A107

    13D Page 12 of 22 Pages    

     

    1.  

    NAMES OF REPORTING PERSONS.

     

    Scott D. Sandell

     

       
    2.  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

     

     

     

     

    (a) ☐

    (b) ☐

    3.  

    SEC USE ONLY

     

     

     

       
    4.  

    SOURCE OF FUNDS (see instructions)

      

    AF

     

       
    5.  

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)     

     

     

     

       ☐
    6.  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States

      

       
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH  

     7.

     

    SOLE VOTING POWER

     

    0 Shares

     

      8.  

    SHARED VOTING POWER

     

    102,478,672 Shares

     

      9.  

    SOLE DISPOSITIVE POWER

     

    0 Shares

     

      10.  

    SHARED DISPOSITIVE POWER

     

    102,478,672 Shares

     

    11.  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    102,478,672 Shares

     

       
    12.  

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions)    

     

     

     

       ☐
    13.  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

      

    6.7%

     

       

     14.

     

    TYPE OF REPORTING PERSON (see instructions)

       

    IN

     

       

     

     

    CUSIP No. 00653A107

    13D Page 13 of 22 Pages    

     

    Item 1. Security and Issuer.

    This Amendment No. 2 to Schedule 13D amends the Schedule 13D originally filed on September 17, 2018 and Amendment No. 1 thereto filed on March 30, 2023, and relates to the ordinary shares, £.001 par value (the “Ordinary Shares”), including Ordinary Shares represented by American Depositary Shares (the “ADS”), with each ADS representing six Ordinary Shares, of Adaptimmune Therapeutics Plc (the “Issuer”) having its principal executive office at 60 Jubilee Avenue, Milton Park, Abingdon, Oxfordshire OX14 4RX, United Kingdom.

     

    Certain terms used but not defined in this Amendment No. 2 have the meanings assigned thereto in the Schedule 13D (including Amendment No. 1 thereto). Except as specifically provided herein, this Amendment No. 2 does not modify any of the information previously reported on the Schedule 13D (including Amendment No. 1 thereto). 

     

     

     

    Item 2. Identity and Background.

    This statement is being filed by:

     

    (a)      New Enterprise Associates 14, L.P. (“NEA 14”) and New Enterprise Associates 16, L.P. (“NEA 16” and collectively with NEA 14, the “Funds”);

     

    (b)      NEA Partners 14, L.P. (“NEA Partners 14”), which is the sole general partner of NEA 14; NEA Partners 16, L.P. (“NEA Partners 16” and collectively with NEA Partners 14, the “GPLPs”), which is the sole general partner of NEA 16; NEA 14 GP, LTD (“NEA 14 GP”), which is the sole general partner of NEA Partners 14; and NEA 16 GP, LLC (“NEA 16 GP” and, collectively with the GPLPs and NEA 14 GP, the “Control Entities”), which is the sole general partner of NEA Partners 16;

     

    (c)      Forest Baskett (“Baskett”), Ali Behbahani (“Behbahani”), Carmen Chang (“Chang”), Anthony A. Florence, Jr. (“Florence”), Patrick J. Kerins (“Kerins”), Mohamad H. Makhzoumi (“Makhzoumi”), and Scott D. Sandell (“Sandell”) (together, the “Managers”) and Peter W. Sonsini (“Sonsini”).

     

    Baskett, Florence, and Sandell (the “Dual Managers”) are directors of NEA 14 GP and managers of NEA 16 GP. Kerins is a director of NEA 14 GP (the “NEA 14 Director”). Behbahani, Chang, and Makhzoumi are managers of NEA 16 GP (the “NEA 16 Managers”). Florence, Makhzoumi, and Sandell are also members of the Executive Committee of NEA Management Company, LLC (the “Executive Committee”).

     

    The persons named in this Item 2 are referred to individually herein as a “Reporting Person” and collectively as the “Reporting Persons.”

     

    The address of the principal business office of the Funds, each Control Entity and Sandell is New Enterprise Associates, 1954 Greenspring Drive, Suite 600, Timonium, MD 21093. The address of the principal business office of Baskett, Behbahani, Chang, and Makhzoumi is New Enterprise Associates, 2855 Sand Hill Road, Menlo Park, California 94025. The address of the principal business office of Florence is New Enterprise Associates, 104 5th Avenue, 19th Floor, New York, NY 10001.

     

    During the five years prior to the date hereof, none of the Reporting Persons has been convicted in a criminal proceeding or has been a party to a civil proceeding ending in a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

     

    Each of NEA 14 and NEA Partners 14 is a Cayman Islands exempted limited partnership. NEA 14 GP is a Cayman Islands exempted company. Each of NEA 16 and NEA Partners 16 is a Delaware limited partnership. NEA 16 GP is a limited liability company organized under the laws of the State of Delaware. Each of the Managers is a United States citizen.

     

     

     

     

    CUSIP No. 00653A107

    13D Page 14 of 22 Pages    

     

     

    Item 5. Interest in Securities of the Issuer.

     

    (a)NEA 14 is the record owner of the NEA 14 Shares. As the general partner of NEA 14, NEA Partners 14 may be deemed to own beneficially the NEA 14 Shares. As the sole general partner of NEA Partners 14, NEA 14 GP may be deemed to own beneficially the NEA 14 Shares. As directors of NEA 14 GP each of the Dual Managers and the NEA 14 Director may be deemed to own beneficially the NEA 14 Shares. As an individual member of the Executive Committee, which committee has been delegated certain approval rights with respect to dispositions of the NEA 14 Shares, Makhzoumi may also be deemed to own beneficially the NEA 14 Shares.

     

    NEA 16 is the record owner of the NEA 16 Shares. As the general partner of NEA 16, NEA Partners 16 may be deemed to own beneficially the NEA 16 Shares. As the sole general partner of NEA Partners 16, NEA 16 GP may be deemed to own beneficially the NEA 16 Shares. As members of NEA 16 GP, each of the Dual Managers and the NEA 16 Managers may be deemed to own beneficially the NEA 16 Shares.

     

    By virtue of their relationship as affiliated entities, whose controlling entities have substantially overlapping individual controlling persons, each of the Funds and the Control Entities may be deemed to share the power to direct the disposition and vote of the Firm Shares.

     

    Each Reporting Person disclaims beneficial ownership of the Firm Shares and the shares held by the other Stockholders other than those shares which such person owns of record.

     

    The percentage of outstanding Ordinary Shares of the Issuer which may be deemed to be beneficially owned by each Reporting Person is set forth on Line 13 of such Reporting Person’s cover sheet. Such percentage was calculated for each Reporting Person based on the 1,532,974,878 Ordinary Shares reported by the Issuer to be outstanding as of April 1, 2024, on the Issuer’s preliminary proxy statement filed with the SEC on April 1, 2024.

     

    (b)Regarding the number of shares as to which such person has:

     

    (i)sole power to vote or to direct the vote: See line 7 of cover sheets

     

    (ii)shared power to vote or to direct the vote: See line 8 of cover sheets

     

    (iii)sole power to dispose or to direct the disposition: See line 9 of cover sheets

     

    (iv)shared power to dispose or to direct the disposition: See line 10 of cover sheets

     

    (c)None of the Reporting Persons has effected any transaction in the Ordinary Shares during the last 60 days.

     

    (d)No other person is known to have the right to receive or the power to direct the receipt of dividends from, or any proceeds from the sale of, Ordinary Shares beneficially owned by any of the Reporting Persons.

     

    (e)Sonsini has ceased to beneficially own five percent (5%) or more of the Issuer’s Ordinary Shares as a result of ceasing to be a director of NEA 14 LTD and manager of NEA 16 GP. Behbahani and Chang have ceased to beneficially own five percent (5%) or more of the Issuer’s Ordinary Shares.

     

     

    Item 6. Contracts, Arrangements, Undertakings or Relationships with Respect to Securities of the Issuer.

    The information provided and incorporated by reference in Item 4 is hereby incorporated by reference. 

     

    Item 7. Material to be Filed as Exhibits.

    Exhibit 1 – Agreement regarding filing of joint Schedule 13D.

    Exhibit 2 – Power of Attorney regarding filings under the Securities Exchange Act of 1934, as amended.

     

     

    CUSIP No. 00653A107

    13D Page 15 of 22 Pages    

    SIGNATURE

     

    After reasonable inquiry and to the best of its knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

     

    EXECUTED this 2nd day of April, 2024.

     

     

     

    NEW ENTERPRISE ASSOCIATES 14, L.P.

     

    By:

    NEA PARTNERS 14, L.P.

    General Partner

     

    By:

    NEA 14 GP, LTD

    General Partner

      

      By:          *                                

     Scott D. Sandell

     Director 

     

    NEA PARTNERS 14, L.P.

     

    By:NEA 14 GP, LTD
    General Partner

     

    By:          *                                

    Scott D. Sandell

    Director

     

      

    NEA 14 GP, LTD

     

    By:          *                                

    Scott D. Sandell

    Director

     

     

     

     

     

     

     

     

     

    CUSIP No. 00653A107

    13D Page 16 of 22 Pages    

     

     

     

     

                     *                        

    Forest Baskett

     

     

                     *                        

    Anthony A. Florence, Jr.

     

     

                     *                        

    Patrick J. Kerins

     

     

                     *                        

    Scott D. Sandell

     

     

                     *                        

    Peter W. Sonsini

     

     

     

     

    NEW ENTERPRISE ASSOCIATES 16, L.P.

     

    By:

    NEA PARTNERS 16, L.P.

    General Partner

     

    By:

    NEA 16 GP, LLC

    General Partner

      

      By:          *                                

     Scott D. Sandell

     Chief Executive Officer 

     

    NEA PARTNERS 16, L.P.

     

    By:NEA 16 GP, LLC
    General Partner

     

    By:          *                                

    Scott D. Sandell

    Chief Executive Officer

     

      

    NEA 16 GP, LLC

     

    By:          *                                

    Scott D. Sandell

    Chief Executive Officer

     

     

     

    CUSIP No. 00653A107

    13D Page 17 of 22 Pages    

     

     

     

     

     

                     *                        

    Forest Baskett

     

     

                     *                        

    Ali Behbahani

     

     

                     *                        

    Carmen Chang

     

     

                     *                        

    Anthony A. Florence, Jr.

     

     

                     *                        

    Mohamad H. Makhzoumi

      

     

                     *                        

    Scott D. Sandell

     

     

                     *                        

    Peter W. Sonsini

     

     

     

     

     

    EXECUTIVE COMMITTEE: 

     

     

                     *                        

    Mohamad H. Makhzoumi

     

     

     

    */s/ Zachary Bambach           

    Zachary Bambach

    As attorney-in-fact

     

     

    This Amendment No. 2 to Schedule 13D was executed by Zachary Bambach on behalf of the individuals listed above pursuant to a Power of Attorney a copy of which is attached as Exhibit 2.

     

     
     

     

    CUSIP No. 00653A107

    13D Page 18 of 22 Pages    

     

    EXHIBIT 1

     

    AGREEMENT

     

    Pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, the undersigned hereby agree that only one statement containing the information required by Schedule 13D need be filed with respect to the ownership by each of the undersigned of shares of stock of Adaptimmune Therapeutics Plc.

     

    EXECUTED this 2nd day of April, 2024.

     

     

     

    NEW ENTERPRISE ASSOCIATES 14, L.P.

     

    By:

    NEA PARTNERS 14, L.P.

    General Partner

     

    By:

    NEA 14 GP, LTD

    General Partner

      

      By:          *                                

     Scott D. Sandell

     Director 

     

    NEA PARTNERS 14, L.P.

     

    By:NEA 14 GP, LTD
    General Partner

     

    By:          *                                

    Scott D. Sandell

    Director

     

      

    NEA 14 GP, LTD

     

    By:          *                                

    Scott D. Sandell

    Director

     

     

     

     

     

     

     

     

     

     

     

    CUSIP No. 00653A107

    13D Page 19 of 22 Pages    

     

     

     

     

     

                     *                        

    Forest Baskett

     

     

                     *                        

    Anthony A. Florence, Jr.

     

     

                     *                        

    Patrick J. Kerins

     

     

                     *                        

    Scott D. Sandell

     

     

                     *                        

    Peter W. Sonsini

     

     

     

     

    NEW ENTERPRISE ASSOCIATES 16, L.P.

     

    By:

    NEA PARTNERS 16, L.P.

    General Partner

     

    By:

    NEA 16 GP, LLC

    General Partner

      

      By:          *                                

     Scott D. Sandell

     Chief Executive Officer 

     

    NEA PARTNERS 16, L.P.

     

    By:NEA 16 GP, LLC
    General Partner

     

    By:          *                                

    Scott D. Sandell

    Chief Executive Officer

     

      

    NEA 16 GP, LLC

     

    By:          *                                

    Scott D. Sandell

    Chief Executive Officer

     

     

     

    CUSIP No. 00653A107

    13D Page 20 of 22 Pages    

     

     

     

     

     

     

                     *                        

    Forest Baskett

     

     

                     *                        

    Ali Behbahani

     

     

                     *                        

    Carmen Chang

     

     

                     *                        

    Anthony A. Florence, Jr.

     

     

                     *                        

    Mohamad H. Makhzoumi

     

     

                     *                        

    Scott D. Sandell

     

     

                     *                        

    Peter W. Sonsini

     

     

     

     

     

    EXECUTIVE COMMITTEE: 

     

     

                     *                        

    Mohamad H. Makhzoumi

     

     

     

    */s/ Zachary Bambach           

    Zachary Bambach

    As attorney-in-fact

     

    This Agreement relating to Schedule 13D was executed by Zachary Bambach on behalf of the individuals listed above pursuant to a Power of Attorney a copy of which is attached hereto as Exhibit 2.

     

     

     

    CUSIP No. 00653A107

    13D Page 21 of 22 Pages    

    EXHIBIT 2

     

    POWER OF ATTORNEY

     

    KNOW ALL MEN BY THESE PRESENTS, that the undersigned hereby constitutes and appoints Zachary Bambach, Nicole Hatcher and Stephanie Brecher, and each of them, with full power to act without the others, his or her true and lawful attorney-in-fact, with full power of substitution, to sign any and all instruments, certificates and documents that may be necessary, desirable or appropriate to be executed on behalf of himself as an individual or in his or her capacity as a direct or indirect general partner, director, officer or manager of any partnership, corporation or limited liability company, pursuant to section 13 or 16 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and any and all regulations promulgated thereunder, including, without limitation, Forms 3, 4 and 5 and Schedules 13D and 13G (and any amendments thereto), and to file the same, with all exhibits thereto, and any other documents in connection therewith, with the Securities and Exchange Commission (the “SEC”), including, but not limited to, signing a Form ID for and on behalf of the undersigned and filing such Form ID with the SEC, and with any other entity when and if such is mandated by the Exchange Act or by the Financial Industry Regulatory Authority, granting unto said attorney-in-fact full power and authority to do and perform each and every act and thing necessary, desirable or appropriate, fully to all intents and purposes as he or she might or could do in person, thereby ratifying and confirming all that said attorney-in-fact, or his or her substitutes, may lawfully do or cause to be done by virtue hereof. This power of attorney is perpetual, unless revoked by the undersigned in a signed writing delivered to each of the foregoing attorneys-in-fact.

     

    IN WITNESS WHEREOF, this Power of Attorney has been signed as of the 29th day of February, 2024.

     

     

    /s/ Peter J. Barris  
    Peter J. Barris  
       
    /s/ Forest Baskett  
    Forest Baskett  
       
    /s/ Ali Behbahani  
    Ali Behbahani  
       
    /s/ Ronald D. Bernal  
    Ronald D. Bernal  
       
    /s/ Ann Bordetsky  
    Ann Bordetsky  
       
    /s/ Carmen Chang  
    Carmen Chang  
       
    /s/ Philip Chopin  
    Philip Chopin  
       
    /s/ Anthony A. Florence, Jr.  
    Anthony A. Florence, Jr.  
       
    /s/ Jonathan Golden  
    Jonathan Golden  
       
    /s/ Scott Gottlieb  
    Scott Gottlieb  

     

     

     

     

     

     

    CUSIP No. 00653A107

    13D Page 22 of 22 Pages    

     

     

     

     

     

    /s/ Mark Hawkins  
    Mark Hawkins  
       
    /s/ Jeffrey R. Immelt  
    Jeffrey R. Immelt  
       
    /s/ Aaron Jacobson  
    Aaron Jacobson  
       
    /s/ Patrick J. Kerins  
    Patrick J. Kerins  
       
    /s/ Hilarie Koplow-McAdams  
    Hilarie Koplow-McAdams  
       
    /s/ Vanessa Larco  
    Vanessa Larco  
       
    /s/ Julio C. Lopez  
    Julio C. Lopez  
       
    /s/ Tiffany Le  
    Tiffany Le  
       
    /s/ Mohamad H. Makhzoumi  
    Mohamad H. Makhzoumi  
       
    /s/ Edward T. Mathers  
    Edward T. Mathers  
       
    /s/ Gregory Papadopoulos  
    Gregory Papadopoulos  
       
    /s/ Kavita Patel  
    Kavita Patel  
       
    /s/ Scott D. Sandell  
    Scott D. Sandell  
       
    /s/ A. Brooke Seawell  
    A. Brooke Seawell  
     
    /s/ Peter Sonsini  

    Peter Sonsini

     
       
    /s/ Melissa Taunton  
    Melissa Taunton  
       
    /s/ Paul E. Walker  
    Paul E. Walker  
       
    /s/ Rick Yang  
    Rick Yang  

     

     

     

    Get the next $ADAP alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ADAP

    DatePrice TargetRatingAnalyst
    7/30/2024$4.00Buy
    H.C. Wainwright
    5/30/2024$3.15Sector Outperform
    Scotiabank
    3/24/2023$3.60Buy
    Bryan Garnier
    1/3/2023$5.00Neutral → Buy
    Guggenheim
    11/9/2022$9.00Neutral → Buy
    Mizuho
    9/22/2021$6.00 → $7.00Equal-Weight
    Wells Fargo
    9/13/2021$6.00 → $7.00Market Perform
    SVB Leerink
    9/7/2021$5.00 → $6.00Market Perform
    SVB Leerink
    More analyst ratings

    $ADAP
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Adaptimmune to Report Q1 2025 Financial and Business Updates on Tuesday, May 13, 2025

      Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - May 7, 2025) - Adaptimmune Therapeutics plc (NASDAQ:ADAP), a company redefining the treatment of solid tumor cancers with cell therapy, will report financial results and provide business updates for the first quarter of 2025, before the US markets open on Tuesday, May 13, 2025. Following the announcement, the Company will host a live webcast at 8:00 a.m. EDT that same day.The press release will be available in the investor section of Adaptimmune's corporate website. A live webcast and replay can be accessed at https://www.gowebcasting.com/14032. Call in information is as follows: 1-833-821-0158 (US or Canada) or 1-647-8

      5/7/25 12:00:00 PM ET
      $ADAP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Adaptimmune Provides Q4 and Full Year 2024 Business Update

      TECELRA® launch momentum accelerating – 10 patients apheresed in Q1 2025 and 3 in 2024; 20 ATCs available; all manufacturing and supply goals achievedLete-cel on track to initiate rolling BLA submission late 2025; approval anticipated 2026Corporate restructure completed in February 2025 and implementing additional cost reduction for PRAME and CD70 programsAt the end of 2024, Adaptimmune had Total Liquidity1 of $152 millionEvaluating all strategic options to maximize shareholder valuePhiladelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - March 20, 2025) - Adaptimmune Therapeutics plc (NASDAQ:ADAP), a company redefining the treatment of solid tumor cancers with cell therapy,

      3/20/25 7:00:00 AM ET
      $ADAP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Adaptimmune to Report Full Year and Q4 2024 Financial and Business Updates on Thursday, March 20, 2025

      Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - March 12, 2025) - Adaptimmune Therapeutics plc (NASDAQ:ADAP), a company redefining the treatment of solid tumor cancers with cell therapy, will report financial results and provide business updates for the fourth quarter and full year ended December 31, 2024, before the US markets open on Thursday, March 20, 2025. Following the announcement, the Company will host a live webcast at 8:00 a.m. EDT that same day.The press release will be available in the investor section of Adaptimmune's corporate website. A live webcast and replay can be accessed at https://www.gowebcasting.com/13966. Call in information is as follows: 1-8

      3/12/25 4:54:00 PM ET
      $ADAP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ADAP
    Leadership Updates

    Live Leadership Updates

    See more
    • Adaptimmune to Report Q1 2025 Financial and Business Updates on Tuesday, May 13, 2025

      Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - May 7, 2025) - Adaptimmune Therapeutics plc (NASDAQ:ADAP), a company redefining the treatment of solid tumor cancers with cell therapy, will report financial results and provide business updates for the first quarter of 2025, before the US markets open on Tuesday, May 13, 2025. Following the announcement, the Company will host a live webcast at 8:00 a.m. EDT that same day.The press release will be available in the investor section of Adaptimmune's corporate website. A live webcast and replay can be accessed at https://www.gowebcasting.com/14032. Call in information is as follows: 1-833-821-0158 (US or Canada) or 1-647-8

      5/7/25 12:00:00 PM ET
      $ADAP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Adaptimmune Provides Q4 and Full Year 2024 Business Update

      TECELRA® launch momentum accelerating – 10 patients apheresed in Q1 2025 and 3 in 2024; 20 ATCs available; all manufacturing and supply goals achievedLete-cel on track to initiate rolling BLA submission late 2025; approval anticipated 2026Corporate restructure completed in February 2025 and implementing additional cost reduction for PRAME and CD70 programsAt the end of 2024, Adaptimmune had Total Liquidity1 of $152 millionEvaluating all strategic options to maximize shareholder valuePhiladelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - March 20, 2025) - Adaptimmune Therapeutics plc (NASDAQ:ADAP), a company redefining the treatment of solid tumor cancers with cell therapy,

      3/20/25 7:00:00 AM ET
      $ADAP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Adaptimmune to Report Full Year and Q4 2024 Financial and Business Updates on Thursday, March 20, 2025

      Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - March 12, 2025) - Adaptimmune Therapeutics plc (NASDAQ:ADAP), a company redefining the treatment of solid tumor cancers with cell therapy, will report financial results and provide business updates for the fourth quarter and full year ended December 31, 2024, before the US markets open on Thursday, March 20, 2025. Following the announcement, the Company will host a live webcast at 8:00 a.m. EDT that same day.The press release will be available in the investor section of Adaptimmune's corporate website. A live webcast and replay can be accessed at https://www.gowebcasting.com/13966. Call in information is as follows: 1-8

      3/12/25 4:54:00 PM ET
      $ADAP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ADAP
    Financials

    Live finance-specific insights

    See more

    $ADAP
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $ADAP
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Adaptimmune Reports Q3 2024 Financial and Business Updates

      Tecelra® launch on track with 9 Authorized Treatment Centers available to initiate patient treatment journey, and the first patient apheresed in Q3; expect first commercial revenues in Q4 and the number of treated patients to accelerate throughout 2025Lete-cel IGNYTE-ESO pivotal trial primary analysis reports 42% overall response rate in synovial sarcoma and myxoid/round cell liposarcoma (MRCLS); full data at CTOS conference on November 16Company restructuring to prioritize commercial sarcoma franchise and R&D programs with highest potential return on invested capital and transformational benefit to patientsPlanned 33% reduction in headcount in Q1, 2025 as part of approximately $300 million

      11/13/24 4:05:00 PM ET
      $ADAP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Adaptimmune Reports Q2 2024 Financial and Business Updates

      Adaptimmune received U.S. FDA accelerated approval of Tecelra® (afami-cel), the first approved engineered cell therapy for a solid tumorPatients can begin treatment journey; biomarker testing available; Adaptimmune systems ready to receive ordersAt the end of Q2, Adaptimmune had Total Liquidity[1] of $214.8 millionPhiladelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - August 12, 2024) - Adaptimmune Therapeutics plc (NASDAQ:ADAP), a company redefining the treatment of solid tumor cancers with cell therapy, today reports financial results and business updates for the second quarter ended June 30, 2024. The Company will host a live webcast at 8:00 a.m. EDT (1:00 p.m. BST) tod

      8/12/24 7:00:00 AM ET
      $ADAP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Adaptimmune Receives U.S. FDA Accelerated Approval of TECELRA® (afamitresgene autoleucel), the First Approved Engineered Cell Therapy for a Solid Tumor

      Approved for advanced MAGE-A4+synovial sarcoma in adults with certain HLA types who have received prior chemotherapy TECELRA is the first new treatment option for people with synovial sarcoma in more than a decade Adaptimmune to hold webcast at https://www.gowebcasting.com/13428 on August 2, at 8:00 a.m. EDT Adaptimmune Therapeutics plc (NASDAQ:ADAP), a company working to redefine the treatment of solid tumor cancers with cell therapy, today announced U.S. Food and Drug Administration (FDA) accelerated approval of TECELRA® (afamitresgene autoleucel) for the treatment of adults with unresectable or metastatic synovial sarcoma who have received prior chemotherapy, are HLA-A*02:01P, -A*0

      8/1/24 8:20:00 PM ET
      $ADAP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • H.C. Wainwright initiated coverage on Adaptimmune Therapeutics with a new price target

      H.C. Wainwright initiated coverage of Adaptimmune Therapeutics with a rating of Buy and set a new price target of $4.00

      7/30/24 6:31:41 AM ET
      $ADAP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Scotiabank initiated coverage on Adaptimmune Therapeutics with a new price target

      Scotiabank initiated coverage of Adaptimmune Therapeutics with a rating of Sector Outperform and set a new price target of $3.15

      5/30/24 7:25:43 AM ET
      $ADAP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Bryan Garnier initiated coverage on Adaptimmune Therapeutics with a new price target

      Bryan Garnier initiated coverage of Adaptimmune Therapeutics with a rating of Buy and set a new price target of $3.60

      3/24/23 9:09:04 AM ET
      $ADAP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Chief Operating Officer Bertrand William C Jr

      4 - Adaptimmune Therapeutics PLC (0001621227) (Issuer)

      2/20/25 5:35:34 PM ET
      $ADAP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Chief Scientific Officer Brewer Joanna Elizabeth

      4 - Adaptimmune Therapeutics PLC (0001621227) (Issuer)

      2/20/25 5:34:48 PM ET
      $ADAP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Chief Patient Supply Officer Lunger John

      4 - Adaptimmune Therapeutics PLC (0001621227) (Issuer)

      2/20/25 5:33:25 PM ET
      $ADAP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ADAP
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Adaptimmune Therapeutics plc

      SC 13G/A - Adaptimmune Therapeutics PLC (0001621227) (Subject)

      11/13/24 9:04:55 AM ET
      $ADAP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13D/A filed by Adaptimmune Therapeutics plc (Amendment)

      SC 13D/A - Adaptimmune Therapeutics PLC (0001621227) (Subject)

      4/2/24 8:38:07 PM ET
      $ADAP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Adaptimmune Therapeutics plc (Amendment)

      SC 13G/A - Adaptimmune Therapeutics PLC (0001621227) (Subject)

      3/26/24 11:59:28 AM ET
      $ADAP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ADAP
    SEC Filings

    See more
    • Adaptimmune Therapeutics plc filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

      8-K - Adaptimmune Therapeutics PLC (0001621227) (Filer)

      5/1/25 4:15:32 PM ET
      $ADAP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form DEF 14A filed by Adaptimmune Therapeutics plc

      DEF 14A - Adaptimmune Therapeutics PLC (0001621227) (Filer)

      4/25/25 8:02:51 AM ET
      $ADAP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form S-3 filed by Adaptimmune Therapeutics plc

      S-3 - Adaptimmune Therapeutics PLC (0001621227) (Filer)

      4/18/25 4:32:27 PM ET
      $ADAP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care